Clinical Trial Update: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating CagriSema for weight loss in people with Type 2 diabetes and excess body weight has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Phase 3 | Status: COMPLETED